^
Association details:
| Biomarker: | ALK fusion |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
All patients with nonsquamous NSCLC...alectinib or brigatinib is the optimal first-line treatment for patients with anaplastic lymphoma kinase fusions.
